Ultragenyx
$ 28.62
0.32%
21 Jul - close price
- Market Cap 2,809,898,000 USD
- Current Price $ 28.62
- High / Low $ 29.10 / 28.23
- Stock P/E N/A
- Book Value -2.41
- EPS -5.95
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -6.08 %
- 52 Week High 39.89
- 52 Week Low 18.29
About
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.
Analyst Target Price
$52.53
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-12 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-13 | 2024-11-05 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -1.54 | -1.29 | -1.81 | -1.17 | -1.57 | -1.39 | -1.4 | -1.52 | -2.03 | -1.52 | -2.23 | -2.25 |
| Estimated EPS | -1.46 | -1.17 | -1.21 | -1.32 | -1.64 | -1.27 | -1.47 | -1.63 | -1.72 | -1.61 | -2.01 | -2.02 |
| Surprise | -0.08 | -0.12 | -0.6 | 0.15 | 0.07 | -0.12 | 0.07 | 0.11 | -0.31 | 0.09 | -0.22 | -0.23 |
| Surprise Percentage | -5.4795% | -10.2564% | -49.5868% | 11.3636% | 4.2683% | -9.4488% | 4.7619% | 6.7485% | -18.0233% | 5.5901% | -10.9453% | -11.3861% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RARE
2026-07-21 12:33:27
Ultragenyx Pharmaceutical stock has experienced a significant downturn, sliding 20% over a nine-day losing streak. The article headline indicates this substantial drop in share value for the pharmaceutical company. Limited content provided, so specific causes are not detailed.
2026-07-21 09:41:27
Ultragenyx Pharmaceutical (RARE) stock has experienced a 9-day losing streak, resulting in a 20.5% loss and a $738 million reduction in market value. This decline brings the company's market value to $2.9 billion. The market is scrutinizing the biotech firm's financial performance, noting its 13.5% revenue growth over the last twelve months but a negative operating margin of -83.8% and negative trailing earnings, contrasting sharply with S&P 500 medians.
2026-07-20 22:53:00
The article discusses how Ultragenyx Pharmaceutical's (RARE stock) valuation is influenced by its cash reserves, ongoing clinical progress in rare diseases, and commercialization efforts. It highlights the balance between strong cash positions and recurring operating losses typical of biotech companies, emphasizing the importance of pipeline milestones, regulatory catalysts, and commercial execution for long-term value. The overview also touches on competitive landscape, margin profile, and the regulatory environment impacting the rare disease sector.
2026-07-20 22:41:27
This article from Stock Traders Daily analyzes Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), highlighting a prevailing weak sentiment and an exceptional 68.4:1 risk-reward short setup. It details three AI-generated institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, alongside multi-timeframe signal analysis. The report also provides specific entry, target, and stop-loss levels for each strategy.
2026-07-19 04:40:34
Ultragenyx Pharmaceutical (RARE) is burning cash despite having four approved rare-disease drugs, due to structural inefficiencies and challenges in scaling gene-therapy manufacturing. The author argues that the company's commercial model is inefficient, its royalty streams are diluted, and current restructuring efforts are defensive rather than strategic. These factors thin safety margins and make the path to profitability by 2027 highly uncertain.
2026-07-19 00:10:49
Ultragenyx Pharmaceutical (RARE) stock is experiencing a valuation reassessment, with its rare disease portfolio and late-stage pipeline driving investor focus. While a narrative suggests the stock is 43.7% undervalued at $52.05 against its current $29.28 price, based on strong growth potential in rare disease and gene therapy, another view highlights potential risks. The P/S ratio of 4.3x is cheaper than the industry average but above its fair ratio, indicating mixed signals for investors considering upside potential versus valuation risk.
